1. Home
  2. MLYS vs VTEX Comparison

MLYS vs VTEX Comparison

Compare MLYS & VTEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • VTEX
  • Stock Information
  • Founded
  • MLYS 2019
  • VTEX 1999
  • Country
  • MLYS United States
  • VTEX Cayman Islands
  • Employees
  • MLYS N/A
  • VTEX N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • VTEX Computer Software: Prepackaged Software
  • Sector
  • MLYS Health Care
  • VTEX Technology
  • Exchange
  • MLYS Nasdaq
  • VTEX Nasdaq
  • Market Cap
  • MLYS 893.0M
  • VTEX 863.0M
  • IPO Year
  • MLYS 2023
  • VTEX 2021
  • Fundamental
  • Price
  • MLYS $14.66
  • VTEX $5.10
  • Analyst Decision
  • MLYS Strong Buy
  • VTEX Strong Buy
  • Analyst Count
  • MLYS 3
  • VTEX 2
  • Target Price
  • MLYS $27.00
  • VTEX $10.00
  • AVG Volume (30 Days)
  • MLYS 2.0M
  • VTEX 853.7K
  • Earning Date
  • MLYS 05-08-2025
  • VTEX 05-06-2025
  • Dividend Yield
  • MLYS N/A
  • VTEX N/A
  • EPS Growth
  • MLYS N/A
  • VTEX N/A
  • EPS
  • MLYS N/A
  • VTEX 0.06
  • Revenue
  • MLYS N/A
  • VTEX $226,709,000.00
  • Revenue This Year
  • MLYS N/A
  • VTEX $17.22
  • Revenue Next Year
  • MLYS N/A
  • VTEX $18.43
  • P/E Ratio
  • MLYS N/A
  • VTEX $82.26
  • Revenue Growth
  • MLYS N/A
  • VTEX 12.50
  • 52 Week Low
  • MLYS $8.24
  • VTEX $4.20
  • 52 Week High
  • MLYS $18.38
  • VTEX $9.10
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 56.01
  • VTEX 49.62
  • Support Level
  • MLYS $16.15
  • VTEX $4.81
  • Resistance Level
  • MLYS $17.21
  • VTEX $5.26
  • Average True Range (ATR)
  • MLYS 1.30
  • VTEX 0.21
  • MACD
  • MLYS -0.03
  • VTEX 0.10
  • Stochastic Oscillator
  • MLYS 36.19
  • VTEX 81.97

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About VTEX VTEX

Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.

Share on Social Networks: